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Summary Between May 1986 and September 1990 a total of 43 patients with metastatic transitional cell
carcinoma (TCC) of the urinary tract have been treated at our institution with combination chemotherapy
(CMV) consisting of cisplatin 100mg m2 IV day 2; methotrexate 30mg m2 IV days 1,8; and vinblastine
4 mg m-2 IV days 1,8. Chemotherapy was recycled on day 22 and continued for a maximum of six cycles in
responding patients. Of 33 patients with measurable disease 8 (24%) achieved a complete remission (CR). The
median survival for patients achieving a CR was 13 months (range 5-29 +) whilst the median survival for all
43 patients was 7 months (range 1-29 +). Only three patients are still alive - two are disease free. More
effective and/or less toxic chemotherapy regimens are needed for the treatment of patients with metastatic
TCC.
Patients with metastatic transitional cell carcinoma (TCC)
have a median survival of 3 months if untreated (Babaian et
al., 1980). During the 1970's a number of cytotoxic agents
were investigated for their efficacy in treating patients with
advanced TCC. When used as single agents overall response
rates of between 16 and 35% were consistently reported for
cisplatin, methotrexate, cyclophosphamide, doxorubicin, 5-
fluorouracil, and vinblastine (Yagoda et al., 1980). However
complete responses were rare and response durations
brief.
In 1981 investigators from the Northern California
Oncology Group (NCOG) began a phase II study in patients
with metastatic transitional cell carcinoma of a chemotherapy
combination comprising cisplatin, methotrexate and vinblas-
tine (CMV). They reported on the first 60 patients entered
into this study in 1985 (Harker et al., 1985) and documented
a complete response rate of 28% with an overall median
survival of 8 months. In 1983 the Memorial Hospital in New
York began treating patients with advanced TCC with M-
VAC combination chemotherapy which incorporated four of
the most active single agents - methotrexate, vinblastine,
doxorubicin and cisplatin. They reported their initial series in
1985 (Sternberg et al., 1985) and have since added to and
updated their experience (Sternberg et al., 1988; Sternberg et
al., 1989). They have consistently reported encouraging
clinical complete response rates of between 26% and 48%
and in their most recent report the median survival for the
whole group was 13 months with an estimated probability of
4-year survival of 18% +/- 7% (Sternberg et al., 1989).
Both the NCOG and the Memorial groups incorporated
surgical resection of residual disease, where feasible, into
their treatment regimens.
Between May 1986 and September 1990 43 patients with
advanced TCC of the urinary tract have been treated with
CMV chemotherapy at the CRC Wessex Regional Medical
Oncology Unit in Southampton. These patients form the
basis of this report.
Material and methods
The characteristics of the 43 patients are summarised in
Table I. All patients had biopsy proven transitional cell
carcinoma of the bladder (33), renal pelvis (five), ureter (three
or prostate (two). Three patients had tumours with mixed
histology - two with TCC and adenocarcinoma (both pros-
tatic primaries) and 1 with TCC and squamous cell car-
cinoma (bladder primary). There were 35 males and eight
Table I Patient characteristics
Sex: Male
Female
Primary site: Bladder
Renal pelvis
Ureter
Prostate
Previous treatment:
Radiotherapy (RT)
Surgery
None
Surgery + RT
35 (81%)
- 8 (19%)
- 33 (77%)
5 (12%)
- 3 (7%)
2 (4%)
23 (54%)
12 (28%)
- 4 (9%)
- 4 (9%)
Disease sites:
(i) Parenchymal (20 patients):
Bone - 13
Liver - 8
Lung - 7
(ii) Nodal (17 patients);
Abdominal - 17
Pelvic - 15
Cervical - 4
(iii) Locally advanced (6 patients):
females and the median age was 65 years (range 46-75).
During this period ten other patients with advanced TCC
were treated with non-CMV chemotherapy regimens - in
most cases because -of impaired renal function. Patients
treated with chemotherapy were highly selected as advanced
age or serious co-existing medical conditions were regarded
as contraindications to this form of therapy.
Three patients presented with metastatic disease and were
treated with primary chemotherapy. The remaining patients
had received initial treatment for their primary disease.
Twenty-three patients had received radiotherapy to the blad-
der (a median of 8 months earlier), and 12 patients had
undergone either cystectomy or nephrectomy (a median of 4
months earlier). Three patients had surgery and radiotherapy
for their primary tumour.
Six patients had presented following treatment of the
primary with inoperable locally extensive disease in the pel-
vis. Seventeen patients had nodal metastases (pelvic,
abdominal, cervical) only and 20 patients had metastatic
involvement of bone, lung or liver. One patient received
CMV chemotherapy as a result of histologically positive
resection margins at surgery. Thirty-three (77%) of the
patients had disease which was measurable using standard
criteria (determined radiologically). No patient had received
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prior systemic chemotherapy.
All patients were assessed by physical examination, full
blood count, biochemistry screen, liver function tests, chest
x-ray and abdominal ultrasound. In addition most patients
underwent computerised tomographic (CT) scanning of the
abdomen and pelvis; isotope bone scanning was performed in
patients with skeletal symptoms.
All patients had leukocyte counts greater than
3.5 x 109 1'1 neutrophil counts greater than 2.0 x 1091`
and platelet counts greater than 150 x I09- at the time of
commencing chemotherapy. The creatinine clearance was cal-
culated according to the formula of Cockcroft and Gault
(1976) and only patients with a creatinine clearance of
greater than 50 ml min ' were eligible to receive CMV
chemotherapy. Patients with hydronephrosis and levels of
renal impairment precluding CMV chemotherapy had neph-
rostomy tubes inserted in an effort to improve renal function
and make them eligible for CMV treatment.
Patients were treated as outlined in Table II. The day 1
and 8 treatments were given as an outpatient and on day 2
patients were admitted to hospital and prehydrated with
intravenous normal saline. When urine flow was greater than
150 ml h'-I cisplatin was given by 30 min infusion. Treatment
was recycled on day 22 for a total of six cycles unless there
was evidence of progressive disease or intolerable treatment
side-effects. Drug doses were modified according to blood
counts and renal function as outlined in Table II. Seven
patients at the end of the study period received cisplatin at a
dose of 70 mg m2 from the outset in an attempt to limit
cisplatin toxicity. Only one patient underwent post-
chemotherapy surgery, at which a retroperitoneal mass was
resected. No residual tumour was apparent - despite this the
patient relapsed again at this site.
A complete response was defined as complete resolution of
all radiological and clinical evidence of disease as assessed 1
month after the completion of chemotherapy. Partial res-
ponse was defined as a 50% or greater reduction in the
diameter of all tumour masses evident clinically and
radiologically and was the best response recorded at any time
during or immediately after chemotherapy.
Survival was calculated from the date of first
chemotherapy until the date of last follow-up or death.
Results
Thirty-three patients had measurable disease. Of the remain-
ing ten patients, six had pelvic recurrence visualised on CT
which which was not measurable, three had bone metastases
and no other measurable disease and one patient received
chemotherapy for histologically positive surgical resection
margins after cystectomy. Eight of the patients with
measurable disease achieved a complete response (24%) and
Table II CMV chemotherapy regimen
Cisplatin 70 or 100 mg m2 IV Days 2
Methotrexate 30mgm-2 IV Days 1,8
Vinblastine 4mgm-2 IV Days 1,8
(recycle day 22)
Dose modifications:
(1) Renal functiona: Cisplatin MTX
GFR >50mlmin-'- 100% 100%
35-50 ml min-'- 50% 100%
<35 mlmin-'- Omit Omit
(2) Peripheral blood countsb:
WBC Platelet Cisplatin MTX Vinblastine
>3.5 > 100 100% 100% 100%
3.0-3.5 > 100 100% 75% 75%
2.5-2.9 > 100 75% 50% 50%
<2.5 OR <100 Delay treatment at least 1 week
'GFR = glomerular filtration rate as measured by calculated
creatinine clearance. bAll values x 1091 l. MTX = methotrexate.
WBC = total white blood count.
11 patients achieved a partial response (34%) for an overall
response rate of 58%. One of the three patients with bone
metastases as the only metastatic site had complete resolution
of all symptoms and return to normal of the alkaline phos-
phatase level. Of the 33 patients with bladder primaries five
(15%) achieved CR compared with three (30%) out of ten
patients with non-bladder primaries. Six (35%) out of 17
patients with disease confined to nodal metastatic sites
achieved CR compared with only two (12%) out of 17
patients with measurable parenchymal (lung, liver, bone)
metastases. The median duration of CR was 6 months (range
1-20 + months).
The median survival duration for patients achieving CR
was 13 months (range 5-29 + months). Three patients are
still alive, however only two are progression free 19 and 27
months after completing chemotherapy.
Figure 1 shows the survival curve of all 43 patients receiv-
ing CMV chemotherapy. Figure 2 illustrates the survival of
patients grouped according to whether their metastases were
nodal only or parenchymal (six patients with locally extensive
disease alone are excluded). Figure 3 shows the survival
curves for patients with bladder and non-bladder
primaries.
Patients received a median of five cycles of chemotherapy
(range 1-6); 19 patients (43%) received a full six cycles of
chemotherapy. Of these 19 patients only 11 (58%) had six
cycles of cisplatin. One patient refused further chemotherapy
after one cycle of CMV and 23 patients stopped
chemotherapy prematurely because of unresponsive or pro-
gressive disease.
Toxicity
Table III summarises the haematological and renal toxicity
experienced by these patients. Toxicity data is not available
on four patients; three died after completing the first cycle
and one refused further treatment after the first
chemotherapy injections. Ten patients experienced WHO
grade three or four leukopenia in at least one cycle, 18
patients had grade 3 or 4 neutropenia and six patients had
grade 3 anaemia with 13 patients requiring blood transfusion.
Thrombocytopenia was only noted in one patient. Nausea
and vomiting was experienced by the majority ofpatients but
did not lead to the cessation of treatment in any patient with
responsive disease.
Three early (and probably treatment related) deaths occur-
red within a few days of completing the first chemotherapy
cycle. The cause of death was pulmonary oedema in two
(confirmed in one by post-mortem) and gastrointestinal
haemorrhage in the other. In none of these cases was neut-
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Figure 3 Survival of patients related to site of primary in bladder or other (renal, pelvis, ureter or prostate).
Table III Haematological and renal toxicity (data available on 39
patients)
WHO Grade
0 1 2 3 4
1. Haemoglobin 4 12 17 6
2. Leukocyte 9 9 11 8 2
3. Neutrophils 8 1 12 9 9
4. Platelets 38 - 1
5. Renal 7 21 4 1
ropenia demonstrated, though in two, elevation of serum
creatinine at the time of day 8 chemotherapy was apparent.
The other two deaths occurred during the 3rd and 4th cycles
respectively. One patient developed diabetic ketoacidosis
(probably related to dexamethasone administration as an
antiemetic) and died of gastrointestinal haemorrhage; the
other died during an unexplained acute confusional state,
almost certainly related to an exacerbation of chronic obs-
tructive airways disease. These latter two deaths were not
related to renal dysfunction or bone marrow suppression.
None of the deaths occurred at the anticipated time of the
nadir in peripheral blood counts.
Discussion
There can be no doubt that for many patients with metas-
tatic TCC combination chemotherapy can produce rapid and
gratifying relief of symptoms associated with metastatic
disease; in particular skeletal pain and leg oedema. Set
against this is the undoubted toxicity of combination
chemotherapy in this relatively aged population, especially
when cisplatin is administered.
We have presented our experience of administering CMV
chemotherapy to 43 patients with advanced transitional cell
carcinoma. We have reported a complete remission rate in
patients with measurable disease of 24% with an overall
median survival of 7 months. The results are somewhat
disappointing in such a selected group of patients. Many
patients referred for treatment were too elderly or frail to
receive chemotherapy and ten patients had renal impairment
which precluded CMV chemotherapy.
We included ten patients in our report who did not have
measurable disease. The difficulties in radiological assessment
of disease in the pelvis accounted for most of these cases.
Other groups have similarly included significant numbers of
such patients (Harker et al., 1985; Tannock et al., 1989). We
believe that this more accurately reflects the true patient
population with advanced TCC. In comparison the M-VAC
series from the Memorial Hospital included only three such
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patients out of a total of 133 (Stemnberg et al., 1989). In our
series those patients with locally advanced non-measurable
disease had an inferior outcome compared with the rest of
the group (median survival 5 months; range 1-16 months).
To have excluded them from our series would have artifically
raised the median survival. Whether patients with locally
infiltrative (but unmeasurable) disease in the pelvis have an
inherently worse outlook than those with more distant metas-
tases is unknown although similar observations have been
made in the chemotherapy of advanced cervical carcinoma
(Potter et al., 1989).
Our overall results are remarkably similar to those
reported by Harker et al. (1985) who first reported the use of
CMV chemotherapy for this condition. The results are not as
impressive as the M-VAC data from the Memorial Hospital
(Stemnberg et al., 1989) but comparisons between different
patient populations and treatments are not possible. In fact
data on M-VAC and CMV from other centres is surprisingly
sparse; one group however has been unable to reproduce the
high response rates to M-VAC reported by the Memorial
Hospital (Tannock et al., 1989).
CMV proved a toxic regimen in our treatment population.
Three early deaths were probably treatment related but no
definitive proof was available. Toxic deaths have been
reported in other series in approximately 2-4% of cases
(Harker et al., 1985; Hillcoat et al., 1989; Logothetis et al.,
1990a; Stemnberg et al., 1989; Tannock et al., 1989).
Too few randomised studies of sufficient size have been
conducted to direct oncologists in the choice of treatment for
advanced TCC, and most of these have been performed on
the assumption that cisplatin is the superior drug for this
condition. The National Bladder Cancer Collaborative
Group compared cisplatin with cisplatin and cyclophos-
phamide in a randomised trial and 131 patients were entered
(Soloway et al., 1983). No significant differences in response
or survival were noted between the two groups but a study of
this size was unlikely to reveal anything other than large
treatment differences. Similarly the Southeastern Cancer
Study Group Trial (Troner et al., 1987) showed no
differences between cisplatin alone and cisplatin, doxorubicin
and cyclophosphamide in combination (116 patients entered).
Hillcoat et al. (1989) compared cisplatin alone with cisplatin
plus methotrexate and reported no significant differences.
The study was small (108 patients) and the potential for
missing significant treatment differences was again noted
(Scher, 1989).
A randomised study between M-VAC and CISCA (cisp-
latin, cyclophosphamide and doxorubicin) performed at the
M.D. Anderson Cancer Center revealed a significant
difference in response rates and overall median survival in
favour of the MVAC group (Logothetis et al., 1990a). A
randomised comparison ofcisplatin alone versus M-VAC has
been reported in abstract form (Loehrer et al., 1990). A
significant difference in response rate (9% versus 33%) in
favour of M-VAC and a 4 month prolongation of median
survival was reported. Whether the absence of doxorubicin
from the CMV regimen and doxorubicin and methotrexate
from the CISCA regimen can explain the superior results for
M-VAC in these trials is unknown. No randomised study has
been performed between CMV and M-VAC.
Future directions in the management of advanced TCC
remain to be defined. Accepting the toxicity of cisplatin-
based chemotherapy becomes questionable when long-term
survivors are rare. In the randomised studies above the
overall response rates to cisplatin alone were only 16%, 20%
and 31% respectively (Troner et al., 1987; Hillcoat et al.,
1989; Soloway et al., 1983). What is beyond question is that
cisplatin is the drug responsible for the most toxicity. In the
absence of new active agents for TCC and considering the
relatively small numbers of long-term survivors after
chemotherapy one approach to the problem is to attempt to
minimise the toxicity of the treatment thereby making it
available to more patients. With this view in mind the MRC
Advanced Bladder Cancer Subgroup from Great Britain have
launched a randomised trial comparing the CMV regimen
(cisplatin dose 70 mg m-2) with the same chemotherapy with-
out the cisplatin (MV).
Even in the event that the CMV regimen were found to be
superior to MV it may still be prudent to confine CMV
treatment to patients with an inherently better outcome.
Younger patients with good performance status could be
selected for the more intensive treatment. Other prognostic
factors could be utilised to determine those patients with a
higher probability of achieving a complete response and pos-
sible long-term survival. In our series those patients with
non-bladder primaries and disease confined to nodal metas-
tatic sites had a significantly longer median survival. How-
ever these results should be interpreted with caution in view
of the small numbers involved in the analysis. Larger trials
are needed to test these prognostic factors and produce new
indicators of treatment outcome.
Another approach adopted by the M.D. Anderson group
is to dose intensify the chemotherapy using haemopoietic
growth factors. They reported impressive response rates with
escalated M-VAC chemotherapy supported by G-CSF in
patients who were primarily resistant to or relapsing from
combination chemotherapy (Logothetis et al., 1990b). How-
ever platelet toxicity in that study was profound and this
approach may not be widely applicable.
The results of ongoing randomised trials will hopefully
provide practical recommendations for oncologists who
manage patients with this common malignancy which is
chemosensitive but largely incurable.
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